Meropenem

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Pancreatitis

Conditions

Pancreatitis

Trial Timeline

Feb 1, 2002 → May 1, 2007

NCT ID

NCT00318994

About Meropenem

Meropenem is a approved stage product being developed by Pfizer for Pancreatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00318994. Target conditions include Pancreatitis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00061438	Approved	Completed	Feb 1, 2003	Dec 1, 2004	Pancreatitis, Acute Necrotizing
NCT00318994	Approved	Completed	Feb 1, 2002	May 1, 2007	Pancreatitis
NCT00318552	Approved	Completed	Jan 1, 2002	Jun 1, 2006	Sepsis

Competing Products

8 competing products in Pancreatitis

See all competitors

Product	Company	Stage	Hype Score
CREON	AbbVie	Pre-clinical	23
Creon36™	AbbVie	Phase 2	52
Nexium (esomeprazole magnesium) + Placebo to Nexium + Viokase 16 (pancrelipase) + Nexium + Viokase 16 + placebo to Nexium	AstraZeneca	Phase 1	33
Infusion of 5 mg/kg Infliximab + Infusion of 10 mg/kg Infliximab	Merck	Phase 2	52
aprepitant + Placebo	Merck	Pre-clinical	23
meropenem	Pfizer	Approved	84
Tanezumab	Pfizer	Phase 2	51
RG1068 (synthetic human secretin)	Repligen	Phase 3	74

Other Products from Pfizer